Journal article

Alamandine reverses hyperhomocysteinemia-induced vascular dysfunction via PKA-dependent mechanisms

Tawar Qaradakhi, Minos Timotheos Matsoukas, Alan Hayes, Emma Rybalka, Martin Caprnda, Kvetoslava Rimarova, Milan Sepsi, Dietrich Busselberg, Peter Kruzliak, John Matsoukas, Vasso Apostolopoulos, Anthony Zulli

CARDIOVASCULAR THERAPEUTICS | WILEY-HINDAWI | Published : 2017

Abstract

INTRODUCTION: Hyperhomocysteinemia (HHcy) impairs nitric oxide endothelium-dependent vasodilation, consequently leading to atherosclerosis, a risk factor for cardiovascular disease. Novel treatments for HHcy are necessary. AIM: We tested the hypothesis that alamandine, a vasoactive peptide of the renin-angiotensin system (RAS), could reverse HHcy-induced vascular dysfunction through the MrgD receptor and that this is mediated by the protein kinase A (PKA) pathway. Furthermore, we sought to determine a putative binding model of alamandine to the MrgD receptor through docking and molecular dynamics simulations. METHOD: The abdominal aorta was excised from New Zealand white rabbits (n = 15) and..

View full abstract

University of Melbourne Researchers